LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 1, 2012, Pages 117-123

  Zinellu, Angelo ^a   Sotgia, Salvatore ^a   Pisanu, Elisabetta ^a   Loriga, Giacomina ^a   Deiana, Luca ^a,b   Satta, Andrea Ercole ^a   Carru, Ciriaco ^a,b  

^a UNIVERSITY OF SASSARI   (Italy)

^b Azienda Ospedaliera Universitaria Arcispedale S Anna   (Italy)

Author keywords

Chronic kidney disease; Homocysteine; Homocysteinylation; LDL; LDL S Hcy

Indexed keywords

ALLANTOIN; APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; THIOL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ALLANTOIN; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL, LDL; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HOMOCYSTINE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; RENAL INSUFFICIENCY, CHRONIC; SIMVASTATIN; SULFHYDRYL COMPOUNDS; URIC ACID;

EID: 84862270704     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.05.006     Document Type: Article

References (33)

1. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. D. Barford The role of cysteine residues as redox-sensitive regulatory switches Curr. Opin. Struct. Biol. 14 2004 679 686
3. V. Cachofeiro, M. Goicochea, S.G. de Vinuesa, P. Oubiña, V. Lahera, and J. Luño Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease Kidney Int. Suppl. 74 2008 S4 S9
4. C. Carru, L. Deiana, S. Sotgia, G.M. Pes, and A. Zinellu Plasma thiols redox status by laser-induced fluorescence capillary electrophoresis Electrophoresis 25 2004 882 889
5. S. Conard, H. Bays, L.A. Leiter, S. Bird, J. Lin, M.E. Hanson, A. Shah, and A.M. Tershakovec Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither Diabetes Obes. Metab. 12 2010 210 218
6. J. Dierkes, S. Westphal, and C. Luley The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels Expert. Opin. Drug. Saf. 3 2004 101 111
7. E. Dounousi, E. Papavasiliou, A. Makedou, K. Ioannou, K.P. Katopodis, A. Tselepis, K.C. Siamopoulos, and D. Tsakiris Oxidative stress is progressively enhanced with advancing stages of CKD Am. J. Kidney Dis. 48 2006 752 760
8. M. Garcia-Calvo, J. Lisnock, H.G. Bull, B.E. Hawes, D.A. Burnett, M.P. Braun, J.H. Crona, H.R. Davis Jr, D.C. Dean, P.A. Detmers, M.P. Graziano, M. Hughes, D.E. Macintyre, A. Ogawa, K.A. O'Neill, S.P. Iyer, D.E. Shevell, M.M. Smith, Y.S. Tang, A.M. Makarewicz, F. Ujjainwalla, S.W. Altmann, K.T. Chapman, and N.A. Thornberry The target of ezetimibe is Niemann-Pick c1-like 1 (npc1l1) Proc. Natl. Acad. Sci. USA 102 2005 8132 8137
9. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N. Engl. J. Med. 351 2004 1296 1370
10. K.A. Hajjar, L. Mauri, A.T. Jacovina, F. Zhong, U.A. Mirza, J.C. Padovan, and B.T. Chait Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine J. Biol. Chem. 273 1998 9987 9993
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection, 2002 Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7-22.
12. B. Hultberg, A. Andersson, and A. Isaksson Protein binding of homocysteine and other thiols in HeLa cell cultures after addition of homocysteine and copper ions Clin. Chim. Acta 269 1998 175 184
13. A.L. Kater, M.C. Batista, and S.R. Ferreira Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects Diabetol. Metab. Syndr. 7 2010 2 34
14. M.S. Kostapanos, H.J. Milionis, and M.S. Elisaf An overview of the extra-lipid effects of rosuvastatin J. Cardiovasc. Pharmacol. Ther. 13 2008 157 174
15. M.S. Kostapanos, A.T. Spyrou, C.C. Tellis, I.F. Gazi, A.D. Tselepis, M. Elisaf, and E.N. Liberopoulos Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress Lipids 46 2011 341 348
16. A.K. Majors, S. Sengupta, B. Willard, M.T. Kinter, R.E. Pyeritz, and D.W. Jacobsen Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin Arterioscler. Thromb. Vasc. Biol. 22 2002 1354 1359
17. H.J. Milionis, J. Papakostas, A. Kakafika, G. Chasiotis, K. Seferiadis, and M.S. Elisaf Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia J. Clin. Pharmacol. 43 2003 825 830
18. H.T. Ong The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient QJM 98 2005 599 614
19. L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J.R. Sowers HMG CoA reductase inhibitors and renoprotection: the weight of the evidence Ther Adv Cardiovasc Dis 1 2007 49 59
20. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, and P.W. Wilson American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention Circulation 108 2003 2154 2169
21. S. Sengupta, H. Chen, T. Togawa, P.M. DiBello, A.K. Majors, B. Büdy, M.E. Ketterer, and D.W. Jacobsen Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine J. Biol. Chem. 276 2001 30111 30117
22. P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, and J. Ostergren ASCOT investigators: prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
23. E.A. Stein, C.M. Ballantyne, E. Windler, P.A. Sirnes, A. Sussekov, Z. Yigit, C. Seper, and C.R. Gimpelewicz Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am. J. Cardiol. 101 2008 490 496
24. A. Undas, E.B. Williams, S. Butenas, T. Orfeo, and K.G. Mann Homocysteine inhibits inactivation of factor Va by activated protein C J. Biol. Chem. 276 2001 4389 4397
25. N.D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am. J. Physiol. Renal Physiol. 290 2006 F262 F272
26. V. Witko-Sarsat, M. Friedlander, T. Nguyen Khoa, C. Capeillère- Blandin, A.T. Nguyen, S. Canteloup, J.M. Dayer, P. Jungers, T. Drüeke, and B. Descamps-Latscha Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure J. Immunol. 161 1998 2524 2532
27. M.I. Yilmaz, M. Saglam, K. Caglar, E. Cakir, A. Sonmez, T. Ozgurtas, A. Aydin, T. Eyileten, O. Ozcan, C. Acikel, M. Tasar, G. Genctoy, K. Erbil, A. Vural, and C. Zoccali The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine Am. J. Kidney Dis. 47 2006 42 50
28. A. Zinellu, C. Carru, F. Galistu, M.F. Usai, G.M. Pes, G. Baggio, G. Federici, and L. Deiana N-methyl-D-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement Electrophoresis 24 2003 2796 2804
29. A. Zinellu, S. Sotgia, E. Zinellu, M. Formato, S. Manca, S. Magliona, R. Ginanneschi, L. Deiana, and C. Carru Distribution of low-density lipoproteinbound low-molecular-weight thiols: a new analytical approach Electrophoresis 27 2006 2575 2581
30. A. Zinellu, E. Zinellu, S. Sotgia, M. Formato, G.M. Cherchi, L. Deiana, and C. Carru Factors affecting S-homocysteinylation of LDL apoprotein B Clin. Chem. 52 2006 2054 2059
31. A. Zinellu, S. Sotgia, B. Scanu, G. Pintus, A.M. Posadino, A. Cossu, L. Deiana, S. Sengupta, and C. Carru S-homocysteinylated LDL apolipoprotein B adversely affects human endothelial cells in vitro Atherosclerosis 206 2009 40 46
32. A. Zinellu, G. Loriga, B. Scanu, E. Pisanu, M. Sanna, L. Deiana, A.E. Satta, and C. Carru Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease Am. J. Nephrol. 32 2010 242 248
33. A. Zinellu, S. Sotgia, L. Deiana, and C. Carru Field-amplified sample injection combined with pressure-assisted capillary electrophoresis UV detection for the simultaneous analysis of allantoin, uric acid, and malondialdehyde in human plasma Anal. Bioanal. Chem. 399 2011 2855 2861